Was the GLP-1 Problem Always Cost? - Summary - MDSpire
Commentary & Perspectives

Was the GLP-1 Problem Always Cost?

A JAMA Viewpoint argues the BALANCE model targets the leading cause of discontinuation.

Share

In a recent JAMA Viewpoint, Cleveland Clinic researchers Hamlet Gasoyan, DS, and Michael B. Rothberg, MD, analyze the implications of the CMS BALANCE model for GLP-1 medications for obesity. With 16 state Medicaid programs initially covering these drugs, four have since withdrawn support, reflecting ongoing challenges. The BALANCE model, introduced in December 2025, aims to negotiate pricing and coverage for obesity medications under Medicare and Medicaid, highlighting the need for widespread stakeholder participation to combat cost-related treatment discontinuation. Advocacy for participation is crucial for successful implementation by 2026.

Original Source(s)

Was the GLP-1 Problem Always Cost?

  • by Kerri Miller

  • April 3, 2026

Related Content

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

PFAS Exposure Linked to Faster Epigenetic Aging 

Epigenetic clock analysis ties PFNA exposure to faster biological aging, particularly in men aged 50–64 

  • April 1, 2026

  • 2 min
Prednisolone Linked to Metabolic Benefits

A randomized crossover trial found slower bone turnover and no safety differences compared with standard hydrocortisone regimens